RAD52 and cancer: In concordance, inhibition of RAD52 DNA binding activity by small peptide aptamer exerted synthetic lethality in BRCA1 and BRCA2 mutated cancer cells [10] and shRNA-mediated downregulation of RAD52 is lethal in tumor cell lines carrying BRCA2 inactivating mutations [9].